Drug Profile
Research programme: antibody-based cancer therapeutics - Affimed Therapeutics/InNexus Biotechnology
Latest Information Update: 30 Oct 2013
Price :
$50
*
At a glance
- Originator Affimed Therapeutics; InNexus Biotechnology
- Developer Affimed Therapeutics
- Class Monoclonal antibodies
- Mechanism of Action Apoptosis stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 30 Oct 2013 Discontinued - Preclinical for Cancer in Germany (Parenteral)
- 30 Oct 2013 Discontinued - Preclinical for Cancer in USA (Parenteral)
- 11 Apr 2006 Preclinical trials in Cancer in Germany (Parenteral)